Clinical Trial Update: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) [Phase 2]

View source ↗

Summary

An extension study evaluating long-term safety and efficacy of ABT-126 in subjects with schizophrenia; the Phase 2 trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ABT-126

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED